Simulations Plus (NASDAQ:SLP) Releases FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share guidance of $1.07 to $1.20 for the period, compared to the consensus earnings per share estimate of $0.63. The company issued revenue guidance of $90 million to $93 million, compared to the consensus revenue estimate of $91.76 million.

Simulations Plus Trading Down 0.7 %

SLP stock traded down $0.24 during trading on Wednesday, reaching $34.01. 340,193 shares of the stock were exchanged, compared to its average volume of 126,202. The firm’s 50 day moving average is $33.35 and its 200 day moving average is $40.87. The firm has a market cap of $680.54 million, a P/E ratio of 71.35 and a beta of 0.69. Simulations Plus has a twelve month low of $29.37 and a twelve month high of $51.22.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Craig Hallum reissued a “buy” rating and issued a $56.00 price target on shares of Simulations Plus in a research report on Wednesday, July 3rd. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Thursday, September 12th. JMP Securities initiated coverage on shares of Simulations Plus in a report on Tuesday, July 16th. They issued a “market perform” rating on the stock. Finally, KeyCorp started coverage on shares of Simulations Plus in a research report on Monday, July 29th. They issued an “overweight” rating and a $47.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $56.00.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $31.26, for a total transaction of $625,200.00. Following the sale, the director now owns 3,481,592 shares of the company’s stock, valued at $108,834,565.92. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 60,750 shares of company stock worth $2,145,055 over the last quarter. 20.90% of the stock is currently owned by company insiders.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.